Shots:
- The EUA is based on P-III study evaluating regdanvimab vs PBO in adults with COVID-19 who do not require supplemental oxygen & are at high risk of progression to severe COVID-19
- The results demonstrated a 72% reduction in risk of COVID-19 related hospitalization or death in high-risk patients & 70% for all patients, shortened time to clinical recovery (4.7 vs 4.9 days). The therapy also showed a safety, tolerability, antiviral effect & efficacy profile
- Additionally, in vitro & in vivo studies demonstrated the potency of regdanvimab against multiple variants of concern including Alpha, Beta, Gamma & Delta variants. The therapy also showed strong neutralizing capability against Lambda variant
Click here to read full press release/ article | Ref: Celltrion | Image: Pulse News
The post Celltrion’s Regdanvimab (CT-P59) Receives the ANVISA’s EUA for the Treatment of COVID-19 in Brazil first appeared on PharmaShots.
